Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates
View Patent ↗The invention relates to compositions and methods for use in treating skeletal system disorders in a vertebrate at risk for bone loss, and in treating conditions that are characterized by the need for bone growth, in treating fractures, and in treating cartilage disorders. More specifically, the invention concerns the use of NO-bisphosphonate assembly for enhancing bone growth.
1. A method to enhance bone formation in a vertebrate animal comprising administering to the vertebrate animal in need of such enhancement a therapeutically-effective amount of a covalent conjugate consisting of a bisphosphonate and a nitric oxide (NO) releasing compound, (an NO-bisphosphonate).
2. The method of claim 1 wherein the bisphosphonate is alendronate, pamidronate, clodronate, zoledronate, risedronate, etidronate, ibandronate, tiludronate, neridronate, olpadronate, incadronate or YH529.
3. The method of claim 1 wherein the vertebrate animal is a mammal.
4. The method of claim 3 wherein the mammal is a human.
5. The method of claim 1 wherein the NO-bisphosphonate is administered with a pharmaceutically acceptable carrier or excipient.
6. The method of claim 1 wherein the animal has/is suffering from osteoporosis, a bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, bone graft, bone segmental defect, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery degenerative joint condition, post-dental implantation, or cartilage disorder or injury.
7. The method of claim 1 further comprising administering to the animal an additional agent that enhances bone growth or decreases bone resorption.
8. The method of claim 7 wherein the agent is a bone morphogenic protein, growth hormone, estrogen, statin, bisphosphonate, osteogenic factor, anti-resorptive agent, cartilage-derived morphogenic protein, differentiating factor, bone-growth stimulating compound, NF-κB inhibitor, proteasomal inhibitor, proteasomal production inhibitor, or steroid.
9. The method of claim 7 wherein the conjugate and additional agent are administered simultaneously or sequentially.
10. The method of claim 7 wherein the conjugate and additional agent are formulated in a single pharmaceutical formulation or each is formulated in a separate pharmaceutical formulation.